Sökresultat - Ingrid Gause‐Nilsson
- Visas 1 - 20 av 26 resultat
- Gå till nästa sida
-
1
-
2
-
3
Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomi... av Burkhard Göke, Baptist Gallwitz, Johan G. Eriksson, Åsa Hellqvist, Ingrid Gause‐Nilsson
Publicerad 2013Artigo -
4
-
5
-
6
Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy a... av Michał Nowicki, Ivan Rychlík, Hermann Haller, Mark Warren, Lisa Suchower, Ingrid Gause‐Nilsson, K-M. Schützer
Publicerad 2011Artigo -
7
Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled... av William T. Cefalu, Lawrence A. Leiter, Tjerk W.A. de Bruin, Ingrid Gause‐Nilsson, Jennifer Sugg, Shamik Parikh
Publicerad 2015Artigo -
8
Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non... av Björn Fagerberg, S. Edwards, T Halmos, J Łopatyński, H. Schuster, Steen Stender, Grethe Støa-Birketvedt, Serena Tonstad, Sigrún Halldórsdóttir, Ingrid Gause‐Nilsson
Publicerad 2005Artigo -
9
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58 av Avivit Cahn, Stephen D. Wiviott, Ofri Mosenzon, Erica L. Goodrich, Sabina A. Murphy, Ilan Yanuv, Aliza Rozenberg, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Ingrid Gause‐Nilsson, Anna Maria Langkilde, Marc S. Sabatine, Itamar Raz
Publicerad 2022Artigo -
10
<scp>DECLARE‐TIMI</scp> 58: Participants’ baseline characteristics av Itamar Raz, Ofri Mosenzon, Marc P. Bonaca, Avivit Cahn, Eri Kato, Michael G. Silverman, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Ingrid Gause‐Nilsson, Anna Maria Langkilde, Peter A. Johansson, Marc S. Sabatine, Stephen D. Wiviott
Publicerad 2018Artigo -
11
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial av Kazuma Oyama, Itamar Raz, Avivit Cahn, Julia Kuder, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Kyong Soo Park, Assen Goudev, Rafael Díaz, Jindřich Špinar, Ingrid Gause‐Nilsson, Ofri Mosenzon, Marc S. Sabatine, Stephen D. Wiviott
Publicerad 2021Artigo -
12
Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from <scp>DECLARE‐TIMI</scp> 58 av Avivit Cahn, Stephen D. Wiviott, Ofri Mosenzon, Sabina A. Murphy, Erica L. Goodrich, Ilan Yanuv, Aliza Rozenberg, John Wilding, Lawrence A. Leiter, Deepak L. Bhatt, Darren K. McGuire, León Litwak, Adriaan Kooy, Ingrid Gause‐Nilsson, Martin Fredriksson, Anna Maria Langkilde, Marc S. Sabatine, Itamar Raz
Publicerad 2020Artigo -
13
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study av Avivit Cahn, Ofri Mosenzon, Stephen D. Wiviott, Aliza Rozenberg, Ilan Yanuv, Erica L. Goodrich, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Ingrid Gause‐Nilsson, Martin Fredriksson, Peter A. Johansson, Anna Maria Langkilde, Marc S. Sabatine, Itamar Raz
Publicerad 2019Artigo -
14
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58 av Marc P. Bonaca, Stephen D. Wiviott, Thomas A. Zelniker, Ofri Mosenzon, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, Erica L. Goodrich, Remo Furtado, John Wilding, Avivit Cahn, Ingrid Gause‐Nilsson, Per Johanson, Martin Fredriksson, Peter A. Johansson, Anna Maria Langkilde, Itamar Raz, Marc S. Sabatine
Publicerad 2020Artigo -
15
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in... av Thomas A. Zelniker, David A. Morrow, Ofri Mosenzon, Erica L. Goodrich, Petr Jarolı́m, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Christoph Bode, Basil S. Lewis, Ingrid Gause‐Nilsson, Anna Maria Langkilde, Martin Fredriksson, Itamar Raz, Marc S. Sabatine, Stephen D. Wiviott
Publicerad 2020Artigo -
16
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes av Thomas A. Zelniker, Itamar Raz, Ofri Mosenzon, Jamie P. Dwyer, Hiddo H. J. L. Heerspink, Avivit Cahn, Erica L. Goodrich, KyungAh Im, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Ingrid Gause‐Nilsson, Anna Maria Langkilde, Marc S. Sabatine, Stephen D. Wiviott
Publicerad 2021Artigo -
17
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus av Thomas A. Zelniker, Marc P. Bonaca, Remo H.M. Furtado, Ofri Mosenzon, Julia Kuder, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Andrzej Budaj, Róbert Gábor Kiss, Francisco Padilla, Ingrid Gause‐Nilsson, Anna Maria Langkilde, Itamar Raz, Marc S. Sabatine, Stephen D. Wiviott
Publicerad 2020Artigo -
18
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial av Meir Schechter, Stephen D. Wiviott, Itamar Raz, Erica L. Goodrich, Aliza Rozenberg, Ilan Yanuv, Sabina A. Murphy, Thomas A. Zelniker, Martin Fredriksson, Peter A. Johansson, Lawrence A. Leiter, Deepak L. Bhatt, Darren K. McGuire, John Wilding, Ingrid Gause‐Nilsson, Avivit Cahn, Anna Maria Langkilde, Marc S. Sabatine, Ofri Mosenzon
Publicerad 2023Artigo -
19
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction av Remo H.M. Furtado, Marc P. Bonaca, Itamar Raz, Thomas A. Zelniker, Ofri Mosenzon, Avivit Cahn, Julia Kuder, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Christian T. Ruff, José Carlos Nicolau, Ingrid Gause‐Nilsson, Martin Fredriksson, Anna Maria Langkilde, Marc S. Sabatine, Stephen D. Wiviott
Publicerad 2019Artigo -
20
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes av Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca, Ofri Mosenzon, Eri Kato, Avivit Cahn, Michael G. Silverman, Thomas A. Zelniker, Julia Kuder, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Christian T. Ruff, Ingrid Gause‐Nilsson, Martin Fredriksson, Peter A. Johansson, Anna-Maria Langkilde, Marc S. Sabatine
Publicerad 2018Artigo
Sökverktyg:
Relaterade ämnen
Internal medicine
Medicine
Diabetes mellitus
Endocrinology
Type 2 diabetes
Dapagliflozin
Myocardial infarction
TIMI
Alternative medicine
Confidence interval
Pathology
Placebo
Cardiology
Hazard ratio
Percutaneous coronary intervention
Heart failure
Kidney disease
Renal function
Thrombolysis
Type 2 Diabetes Mellitus
Urology
Albuminuria
Engineering
Environmental health
Mace
Mechanical engineering
Population
Saxagliptin
Sitagliptin
Stroke (engine)